Want to see GB:VAL full AI Analyst Report?
Top Page
ValiRx plc
(LSE:VAL)
Select Model
Select Model
Rating:42Neutral
Price Target:
0.16 p
▼(-60.50% Downside)
Action:Reiterated
Date:06/28/26
The score is primarily constrained by weak financial performance—tiny revenue, sustained losses, and ongoing cash burn that is eroding equity—despite low debt. Technicals also detract, with the stock trading below major moving averages and negative MACD, indicating a strong downtrend. Valuation metrics provide limited support due to negative earnings and no dividend yield data.
Positive Factors
Low Leverage
Very low debt materially reduces financial risk and interest burden, preserving flexibility to fund R&D or structure partnerships. For an early-stage biotech this durable capital structure lowers insolvency risk and improves ability to secure staged, non-dilutive funding or collaborations.
Negative Factors
Persistent Cash Burn
Sustained negative operating and free cash flow shows the company cannot self-fund development. This structural cash burn forces recurring external financing, raising dilution risk and potentially limiting ability to advance multiple programs or meet clinical timelines without partner funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low debt materially reduces financial risk and interest burden, preserving flexibility to fund R&D or structure partnerships. For an early-stage biotech this durable capital structure lowers insolvency risk and improves ability to secure staged, non-dilutive funding or collaborations.
Read all positive factors
ValiRx plc (VAL) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£2.11M
Dividend YieldN/A
Average Volume (3M)1.10M
Price to Earnings (P/E)―
Beta (1Y)0.84
Revenue Growth-36.97%
EPS Growth71.72%
CountryUK
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,320,301,000
10 Day Avg. Volume510,641
30 Day Avg. Volume1,099,814
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.49
Price to Sales (P/S)44.16
P/FCF Ratio-0.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ValiRx plc Business Overview & Revenue Model
Company Description
ValiRx plc is a UK-based biopharmaceutical company dedicated to pioneering oncology therapeutics and companion diagnostics. Among its primary drug candidates is VAL201, a small molecule that has progressed through Phase I/II trials, aiming to trea...
How the Company Makes Money
ValiRx plc’s primary way of making money is through the out-licensing and partnering of its drug candidates and associated intellectual property rather than selling finished pharmaceutical products directly. Revenues, when generated, are typically...
ValiRx plc Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 31.37K | 49.77K | 9.60K | 0.00 | 0.00 |
| Gross Profit | -6.25K | -217.22K | -246.04K | -224.27K | -228.79K |
| EBITDA | -2.18M | -1.86M | -2.04M | -2.37M | -1.45M |
| Net Income | -2.23M | -1.92M | -2.04M | -2.41M | -1.55M |
Balance Sheet | |||||
| Total Assets | 2.63M | 4.26M | 3.13M | 3.98M | 3.52M |
| Cash, Cash Equivalents and Short-Term Investments | 791.61K | 1.56M | 174.68K | 1.14M | 593.67K |
| Total Debt | 1.40K | 11.86K | 22.07K | 37.71K | 58.72K |
| Total Liabilities | 235.10K | 346.41K | 226.51K | 149.65K | 109.56K |
| Stockholders Equity | 2.86M | 4.32M | 3.22M | 4.05M | 3.60M |
Cash Flow | |||||
| Free Cash Flow | -1.52M | -1.62M | -2.08M | -1.71M | -1.26M |
| Operating Cash Flow | -1.51M | -1.58M | -1.77M | -1.71M | -1.26M |
| Investing Cash Flow | -13.58K | -38.16K | -306.18K | 0.00 | 0.00 |
| Financing Cash Flow | 759.35K | 3.00M | 1.12M | 2.26M | 7.34K |
ValiRx plc Technical Analysis
Negative
0.40
Price Trends
0.21
Negative
0.26
Negative
0.33
Negative
Market Momentum
-0.01
Negative
24.70
Positive
23.65
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:VAL, the sentiment is Negative. The current price of 0.4 is above the 20-day moving average (MA) of 0.18, above the 50-day MA of 0.21, and above the 200-day MA of 0.33, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 24.70 is Positive, neither overbought nor oversold. The STOCH value of 23.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:VAL.
ValiRx plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | £174.35M | -31.70 | 90.29% | ― | ― | 69.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £4.62M | -4.34 | -53.79% | ― | ― | 85.56% | |
47 Neutral | £29.10M | -5.77 | -284.01% | ― | ― | -105.65% | |
42 Neutral | £2.11M | -0.39 | ― | ― | -36.97% | 71.72% | |
42 Neutral | £51.75M | -3.44 | -2807.75% | ― | ― | -28.29% | |
41 Neutral | £22.80M | -5.90 | -1397.43% | ― | ― | 36.67% |
* Healthcare Sector Average
GB:VAL
ValiRx plc
0.16
-0.44
-73.33%
GB:TCF
Evgen Pharma
0.22
-0.05
-17.31%
GB:IMM
ImmuPharma
3.66
1.40
62.44%
GB:SAR
Sareum Holdings
21.00
1.25
6.33%
GB:SCLP
Scancell Holdings
16.80
7.30
76.84%
GB:HEMO
HemoGenyx Pharmaceuticals Plc
761.00
607.75
396.57%
ValiRx plc Corporate Events
Business Operations and StrategyFinancial Disclosures
ValiRx tightens focus and cuts costs as auditors flag going-concern risk
Negative
Jun 22, 2026
ValiRx reported audited results for 2025 showing it has completed a strategic review, sharpened its focus on three core priorities, and reoriented its Inaphaea BioLabs unit to primarily support the company’s own pipeline while selectively pu...
Business Operations and Strategy
ValiRx Ends Dundee Evaluation After Cancer Asset Fails Licensing Criteria
Negative
Jun 22, 2026
ValiRx plc has ended its evaluation collaboration with the University of Dundee’s Drug Discovery Unit and Queen Mary University of London after the cancer-focused project failed to meet the company’s strict criteria for in-licensing. T...
Business Operations and Strategy
ValiRx Ends Stingray Evaluation as It Refocuses on Later-Stage Assets
Negative
Jun 2, 2026
ValiRx has concluded its evaluation agreement with Stingray Bio, under which it conducted in-silico lead optimisation of potency and target selectivity for Stingray’s assets. Although the work produced some interesting results, the assets di...
Business Operations and StrategyPrivate Placements and Financing
ValiRx fast-tracks RNA helicase deal with McGill and plans Canadian spin-out
Positive
Jun 1, 2026
ValiRx has exercised its option over a second-generation, orally available RNA helicase inhibitor developed by McGill University and IRICoR, after its Inaphaea BioLabs unit completed evaluation four months ahead of schedule. The company plans to t...
Business Operations and Strategy
ValiRx Bolsters Cytolytix IP with New European Patent and Oncolytic Platform Filings
Positive
May 27, 2026
ValiRx has strengthened the intellectual property position of its majority-owned subsidiary Cytolytix with the grant of a core European patent covering nanoparticles for anti-cancer peptides, licensed from King’s College London. The award en...
Business Operations and StrategyPrivate Placements and Financing
ValiRx Raises £1.16m in Oversubscribed Retail and Placing Fundraise
Positive
May 21, 2026
ValiRx has completed an oversubscribed WRAP Retail Offer, raising about £150,000 via 75 million new shares at 0.2 pence, bringing total gross proceeds from its wider fundraising, including a placing and subscription, to approximately £1....
Business Operations and StrategyPrivate Placements and Financing
ValiRx Extends £1.15m Fundraise with UK Retail Share Offer and Attached Warrants
Positive
May 18, 2026
ValiRx plc has launched a retail share offer via Winterflood’s Retail Access Platform to raise up to £150,000 by issuing up to 75,000,000 new ordinary shares at 0.2 pence each, matching the price used in a recently completed £1.005...
Business Operations and StrategyPrivate Placements and Financing
ValiRx launches discounted £1.155m raise to fund IP expansion and animal health push
Positive
May 15, 2026
ValiRx plc has launched a fundraising of up to £1.155 million via a discounted placing, a director subscription and a planned retail offer, issuing up to 502.5 million new shares at 0.2 pence and attaching one three-year warrant per new share...
Business Operations and Strategy
ValiRx updates registered office as it advances oncology and women’s health focus
Neutral
Mar 31, 2026
ValiRx plc, a life science company listed on AIM and specialising in early-stage cancer therapeutics and women’s health, leverages its research and drug development expertise to streamline and reduce the cost of progressing novel drug candid...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.